ProMIS Neurosciences, Inc. PMN
At closeNov 5, 2026, 7:32 PM EST
After hours · Nov 5, 7:32 PM ET
- YTD
- -46.56%
- 1 year
- -64.39%
- Market cap
- 32.73M
- EPS (ttm)
- -11.98
- Shares out
- 32.69M
- Forward P/E
- -1.51
- YTD return
- -46.56%
- 1-year return
- -64.39%
- Volume
- 270.03K
- Avg volume
- 137.19K
- Open
- 3.55
- Previous close
- 3.52
- Day's range
- 3.40 – 3.76
- 52-week range
- 2.78 – 27.40
- Beta
- 0.61
- Analysts
- Strong Buy
- Price target
- 7.65 (+109.6%)
- Earnings date
- Aug 8, 2024
2Y -22.23 (-86.33%)
Key statistics
- Enterprise value
- 28.70M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.62
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -12.77M
- Total cash
- 1.02M
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 1.04%
- 50-day average
- 0.9886
- 200-day average
- 1.51
Analyst view
Consensus: strong buy
- Target (low)
- 5.94
- Target (mean)
- 7.65
- Target (high)
- 9.20
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.14 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.13 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.19 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- promisneurosciences.com
News
ProMIS Neurosciences to Participate in Upcoming Conferences in November 
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates 
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026 
Roth Capital Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $15 
12 Health Care Stocks Moving In Friday's Intraday Session 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to Trade 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer 
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
Your note
Sign in to keep a note on PMN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CASHMAN NEIL | Officer and Director | Stock Award(Grant) | Aug 22, 2023 | 114,921 |
| FARFEL GAIL M | Chief Executive Officer | Stock Award(Grant) | Aug 22, 2023 | 55,192 |
| GORDON MICHAEL STEPHEN | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 16, 2024 | 2,217,180 |
| KIRWIN PATRICK D | Director | Purchase | Aug 13, 2024 | 99,096 |
| MALENFANT GAVIN T. | Chief Operating Officer | Stock Award(Grant) | Aug 22, 2023 | 2,660 |
| MILBURY MAX A. | Officer | Stock Award(Grant) | Aug 22, 2023 | 14,997 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Great Point Partners LLC | 8.54% | 2,790,698 | 2.57M | Sep 29, 2024 |
| Armistice Capital, LLC | 8.17% | 2,670,000 | 2.46M | Sep 29, 2024 |
| Sphera Funds Management Ltd. | 5.90% | 1,929,297 | 1.77M | Sep 29, 2024 |
| Ally Bridge Group (NY) LLC | 4.87% | 1,592,605 | 1.47M | Sep 29, 2024 |
| Altium Capital Management, LP | 1.78% | 581,395 | 534.88K | Sep 29, 2024 |
| Heights Capital Management, Inc | 1.18% | 386,894 | 355.94K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 8,622 | 7.93K | Oct 30, 2024 |